- Neuroscience Research and Clinical Trials
-
Clinical Research
- Movement Disorders Clinical Trials
- Neuromodulation Clinical Trials
- Neuromuscular Disorders Clinical Trials
- Nisonger Clinical Trials
- Physical Medicine and Rehabilitation Clinical Trials
- Spine Clinical Trials
- Stroke Clinical Trials
- Brain and Spine Tumor Clinical Trials
- Cognitive and Memory Disorders Clinical Trials
- Epilepsy Clinical Trials
- Research Labs
- Events
- Chronic Brain Injury Discovery Theme
ALS and Motor Neuron Disease
Ataxia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Fascioscapulohumeral Muscular Dystrophy (FSHD)
Myotonic Dystrophy Type 1
Other Conditions
Refractory Generalized Myasthenia Gravis (GMG)
Sporadic Inclusion Body Myositis (IBM)
ALS and Motor Neuron Disease
-
Answer ALS
-
Multi-Center, Randomized Controlled Study of the Neurx® Diaphragm Pacing System™ in Participants with Amyotrophic Lateral Sclerosis (ALS)
-
Skin Fibroblast Isolation for the Derivation of Induced-Pluripotent Stem Cells for Tissue Culture Models of Neurological Disease
-
Study of Soluble Factors in the Cerebral Spinal Fluid in Individuals With Motor Neuron Disease
-
Study to Access the Effects of Medication Tirasemtiv Versus Placebo on Respiratory Function in Patients with ALS
Ataxia
-
Clinical Outcome Measures in Friedreich’s Ataxia
-
A Phase 2 Study of the Safety, Efficacy and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 Mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
-
Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Investigate the Efficacy, Safety and Tolerability of 2 Different Doses of Igpro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – The PATH Study
Fascioscapulohumeral Muscular Dystrophy (FSHD)
-
Preclinical Trial Preparedness in Fascioscapulohumeral Muscular Dystrophy (FSHD)
-
A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biological Activity of ATYR1940 in Adult Patients with Molecularly Defined Genetic Muscular Dystrophies
Myotonic Dystrophy Type 1
-
A Phase 1/2a Blinded, Placebo-Controlled Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Ascending Doses of ISIS 598769 Administered Subcutaneously to Adult Patients With Myotonic Dystrophy Type 1
-
A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1
Other Conditions
-
Genetic and Molecular Characterization of Inherited Neuropathies
-
A Double Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, Efficacy and Preliminary Dose-Response of BAF312 in Patients With Active Dermatomyositis
-
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) in rhGAA Exposed Subjects With Late-Onset Pompe Disease
-
Open-Label Trial of Ranolazine in Myotonia Congenita
-
A Two-Part, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)
-
Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS): A Global, Multi-Center, Longitudinal, Observational Survey of Patients With Documented Transthyretin (TTR) Mutations or Wild-Type TTR Amyloidosis
Refractory Generalized Myasthenia Gravis (GMG)
-
A Phase II Trial of Rituximab in Myasthenia Gravis
-
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (GMG)
-
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacodynamics of Belimumab in Subjects With Generalized Myasthenia Gravis
Sporadic Inclusion Body Myositis (IBM)
-
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Finding, Pivotal, Phase IIb/III Study to Evaluate the Efficacy, Safety and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength and Mobility and Additional Long-Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis
-
Using Next Generation Sequencing to Unravel the Pathogenesis of Sporadic Inclusion Body Myositis (IBM) – The International IBM Consortium Genetic Study